Federal Circuit cancels key Tyvaso patent; Liquidia may launch Yutrepia sooner

UNITED THERAPEUTICS Corp

Court affirmed IPR decision canceling claims of U.S. Patent No. 10,716,793 covering Tyvaso and Tyvaso DPI.
Liquidia can seek final FDA approval for Yutrepia unless the decision is reversed on further appeal.
United Therapeutics can request rehearing or petition the Supreme Court; patent claims remain valid until appeals exhausted.
Separate lawsuit filed Sep 2023 alleges Yutrepia amendments infringe new patent (11,826,327) expiring Jan 2042.
FDA tentatively approved Yutrepia for PAH in Nov 2021; final approval also requires lifting of District Court order.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.